Key result
Inotrope use in cardiogenic shock is linked to ~124% higher hospital mortality.
Why the study?
Does inotrope use affect mortality in patients with cardiogenic shock?
Cohort (n=34,381)
Yes
Does inotrope use affect mortality in patients with cardiogenic shock?
Effect estimate: HR 2.24 (95% CI 2.09-2.39)
Absolute Event Rate: 24.03% vs 12.4%
p-value: p=<0.0001
In patients with cardiogenic shock, low-dose norepinephrine and milrinone may be associated with lower hospital mortality, while high-dose inotropes warrant caution and consideration of supportive therapies.
No takes yet. Share an insight, caveat, or question.
Inotrope use was associated with higher mortality in cardiogenic shock; hypothesis-generating and should not yet change practice.
Gao et al. (2021) conducted a cohort in Cardiogenic shock (n=34,381). Inotropes vs. No inotropes was evaluated on All-cause hospital mortality (HR 2.24, 95% CI 2.09-2.39, p=<0.0001). Inotrope administration in patients with cardiogenic shock was associated with a significantly higher risk of hospital mortality compared to no inotropes (24.03% vs 12.40%, HR 2.24).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: